Topic: Covid Rebound

Researchers at UC San Diego are investigating "COVID rebound" in patients taking Pfizer's Paxlovid, suggesting that current dosing may be insufficient. This has led to calls for adjusted treatment plans and higher dosages. Simultaneously, there is a renewed push for nasal vaccines, which some studies suggest provide better protection against infection than traditional injections.

Reports from the Boston Globe indicate that patients using Pfizer's antiviral pill, Paxlovid, are experiencing a "rebound" of COVID-19 symptoms after completing the treatment. The phenomenon raises questions about the long-term efficacy of the antiviral as a replacement for other treatments.